Andarine was first described in 2001, in a U.S. patent filing by The University of Tennessee Research Corporation. The drug was subsequently under development by the American company GTx Inc. The earliest research on this substance was published in 2004. It used a rat model to investigate the effects of andarine on the prostate, and its potential with benign prostatic hypertrophy. GTX partnered with Ortho Biotech to develop andarine as a medicine for the treatment of cancer cachexia (wasting). The drug entered Phase I human trials, with Phase II trials planned. However, research was discontinued. This substance may have taken a back seat for more recent innovations in this space, which is now becoming quite crowded with research substances. GTx itself seems more focused on ostarine, which has been extensively studied in humans. These days, most papers on andarine look at its use in sports doping. This drug has been on the WADA banned substance list since 2008, and detectable in doping controls since 2010.

Structural Characteristics:
Andarine is an aryl-propionamide-derived SARM. It is close in structure to bicalutamide, an anti-androgen. The
chemical name of andarine is S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-tri-fluoromethyl-phenyl)-propionamide. stocks all SARMs and peptides check us out makes it easy
Roidshop Accepts Zelle, Moneygram, Western Union, GooglePay, Cashapp with Bitcoin (15%OFF)

Check us out 35% off until 9/26/21 with code summer35